中康控股(02361.HK)2024年報：營收淨利雙增長，創新業務規模快速增長，AI賦能助力戰略升級
格隆匯4月24日丨中康控股(02361.HK)公佈2024年度報吿，2024年，公司憑藉穩健的業務經營，實現財務業績增長，顯著提升股東回報。報吿期內，集團實現收入人民幣4.04億元，同比增長1.9%，收入增長主要來自於智慧零售雲及智慧健康管理雲業務收入的增加；毛利為人民幣2.33億元，同比增長4.4%；淨利潤為人民幣1.12億元，同比增長10.8%。公司擬派末期息每股12港仙。
得益於AI大模型應用程度的持續加深，公司在資源高效利用、產品優化升級以及運營成本優化等方面取得顯著成績，全面推動整體效率提升，毛利率由2023財年的56.4%增長至57.8%，提升1.4個百分點，淨利潤率由2023財年的25.5%增長至27.7%，提升2.2個百分點。
報吿期內，創新業務表現矚目，開創全新增長格局。To B端的院內業務持續創新，其中創新藥患者管理業務、智能化iMDT平台業務的商業模式日臻成熟，2024財年B端院內創新業務規模快速增長，營業收入為4840萬元，較上年同比增長約86.5%，標誌着公司已成功實現產品結構的戰略性升級，在B端院外成熟業務之外開創全新的增長格局。
研發方面。2024財年研發費用同比上升約6.0%，重點投向算力基礎設施和高水平研發人才引進，成功打造出專注於醫療健康行業垂直領域的卓睦鳥醫療大模型，夯實了公司現有技術壁壘，推動AI工具的廣泛應用，不僅顯著提升公司的經營管理水平，也為未來產品體系的迭代升級與業績持續增長提供有力支撐。全方位生態體系日益完善，驅動AI產品精準賦能行業高質量發展。
2024年度公司合作的企業級客户共計1,230家，截止2024年12月31日公司累計覆蓋2,853家醫藥零售企業、超17萬家藥店、超460家醫院、超650家體檢機構，公司管理的藥店店員超24.5萬人、藥店會員超2.82億人，連接醫生數量超過13.4萬名。充分展現公司在市場拓展方面的強勁勢頭，為2025年度的經營發展奠定堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
